Types of Tumors

Select tumor types, platforms, and/or phases below to learn more.

Learn more about tumor types that Genentech is researching. Click to expand.

Tumor types
Development platforms
Phases

Development Platforms and Molecular Pathways

  • Breast
  • Gastrointestinal
  • Gynecologic
  • Solid Tumor
  • Antibody Drug Conjugates
  • T-cell Bispecific Antibodies
  • Gastrointestinal
  • Genitourinary
  • Hematology
  • Lung
  • Melanoma
  • Solid Tumor
  • Monoclonal Antibodies
  • Individualized neoantigen specific therapy
  • T-cell Bispecific Antibodies
  • Breast
  • Gastrointestinal
  • Genitourinary
  • Lung
  • Solid Tumor
  • Small Molecules
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Lung
  • Monoclonal Antibodies
  • T-cell Bispecific Antibodies

Investigational Therapies9

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated. 

Phase III

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Solid Tumor
  • Monoclonal Antibodies

Bevacizumab

(anti-VEGF MAb)

 

  • Gastrointestinal
  • Monoclonal Antibodies

Entrectinib
(ROS1/TRK inhibitor)

(RXDX-101, RG6268)b

 

  • Lung
  • Small Molecules

Pertuzumab + trastuzumab fixed-dose combination SC
(anti-HER2 MAbs)

(RG6264)

 

  • Breast
  • Monoclonal Antibodies
  • Hematology
  • Antibody Drug Conjugates

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

Phase II

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • T-cell Bispecific Antibodies

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Gastrointestinal
  • Genitourinary
  • Monoclonal Antibodies

Cobimetinib
(MEK inhibitor)

(RG7421)e

 

  • Breast
  • Gastrointestinal
  • Hematology
  • Solid Tumor
  • Small Molecules

Entrectinib

(ROS1/TRK inhibitor)

(RXDX-101, RG6268)b

 

  • Lung
  • Pan Tumor
  • Small Molecules

Individualized NeoAntigen Specific Immunotherapy (iNeST)

(RG6180)g

 

  • Melanoma
  • Individualized neoantigen specific therapy
  • Hematology
  • Antibody Drug Conjugates

Tiragolumab
(anti-TIGIT MAb)

(MTIG7192A, RG6058)

 

  • Lung
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Breast
  • Hematology
  • Small Molecules

Phase I

  • Solid Tumor
  • T-cell Bispecific Antibodies
  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • T-cell Bispecific Antibodies

Antibody drug conjugate

(RG6109)

 

  • Hematology
  • Antibody Drug Conjugates

Antibody drug conjugate

(RG6148)

 

  • Breast
  • Antibody Drug Conjugates
Page Error

An error occurred while loading this portion of content. We are resolving this issue and apologize for the inconvenience.

Please check back soon for an update.

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Monoclonal Antibodies

BET inhibitor

(TEN-010, RG6146)

 

  • Breast
  • Gynecologic
  • Hematology
  • Solid Tumor
  • Small Molecules

Bevacizumab
(anti-VEGF MAb)

 

  • Gastrointestinal
  • Head and Neck
  • Monoclonal Antibodies
Page Error

An error occurred while loading this portion of content. We are resolving this issue and apologize for the inconvenience.

Please check back soon for an update.

Cobimetinib
(MEK inhibitor)

(RG7421)e

 

  • Gastrointestinal
  • Genitourinary
  • Head and Neck
  • Hematology
  • Small Molecules

Codrituzumab
(anti-glypican 3 MAb)

(CHU)f

 

  • Gastrointestinal
  • Monoclonal Antibodies
Page Error

An error occurred while loading this portion of content. We are resolving this issue and apologize for the inconvenience.

Please check back soon for an update.

Entrectinib

(ROS1/TRK inhibitor)

(RXDX-101, RG6268)b

 

  • Lung
  • Pan Tumor
  • Solid Tumor
  • Small Molecules

FAP-4-1BBL FP

(RG7827)

 

  • Solid Tumor
  • Monoclonal Antibodies

FAP-IL2v FP

(RG7461)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Lung
  • Solid Tumor
  • Monoclonal Antibodies

Glypican-3 x CD3

(CHU)f

 

  • Solid Tumor
  • T-cell Bispecific Antibodies

HER2 x CD3

(RG6194)

 

  • Breast
  • Solid Tumor
  • T-cell Bispecific Antibodies

Individualized NeoAntigen Specific Immunotherapy (iNeST)

(RG6180)g

 

  • Solid Tumor
  • Individualized neoantigen specific therapy

Monoclonal antibody

(RG6123)

 

  • Solid Tumor
  • Monoclonal Antibodies

Monoclonal antibody

(RG6160)

 

  • Hematology
  • Monoclonal Antibodies
Page Error

An error occurred while loading this portion of content. We are resolving this issue and apologize for the inconvenience.

Please check back soon for an update.

Pan-RAF inhibitor

(RG6185)

 

  • Solid Tumor
  • Small Molecules
  • Lung
  • Melanoma
  • Solid Tumor
  • Monoclonal Antibodies

PI3K inhibitor

(GDC-0077, RG6114)

 

  • Breast
  • Solid Tumor
  • Small Molecules
  • Hematology
  • Antibody Drug Conjugates

Raf/MEK dual inhibitor

(CHU)f

 

  • Solid Tumor
  • Small Molecules

Selective estrogen receptor degrader (SERD) 3

(GDC-9545, RG6171)

 

  • Breast
  • Small Molecules

Selicrelumab
(CD40 MAb)

(RG7876)

 

  • Gastrointestinal
  • Gynecologic
  • Head and Neck
  • Lung
  • Solid Tumor
  • Monoclonal Antibodies

Tiragolumab

(anti-TIGIT MAb)

(MTIG7192A, RG6058)

 

  • Solid Tumor
  • Monoclonal Antibodies

Vanucizumab
(ANG2/VEGF biMAb)

(RG7221)

 

  • Gastrointestinal
  • Solid Tumor
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

aDeveloped in collaboration with Array BioPharma. bIgnyta, Inc acquisition. cDeveloped in collaboration with Seattle Genetics. dJoint project with AbbVie. eDeveloped in collaboration with Exelixis. fDeveloped in collaboration with Chugai. gDeveloped in collaboration with BioNTech.

References

  1. Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35. pii: e00225. PMID: 26182432
  2. Polson AG, Yu S-F, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616-623. PMID: 17374736
  3. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222-226. PMID: 28678784
  4. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist. 2007;12:1084-1095. PMID: 17914078
  5. Hanahan D, Weinberg D. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. PMID: 21376230
  6. Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381-405. PMID: 28431241
  7. Bacac M, Klein C, Umana P. CEA TCB: a novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5:e1203498. PMID: 27622073
  8. Bacac M, Fauti T, Sam J, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286-3297. PMID: 26861458 
  9. Roche first-quarter results 2019 presentation. https://www.roche.com/dam/jcr:f03df0f2-852c-47a5-9924-343bfb239c37/en/irp190417.pdf. Accessed April 18, 2019.